EP2305231A1 — Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
Assigned to Novartis AG · Expires 2011-04-06 · 15y expired
What this patent protects
A pharmaceutical composition comprising the renin inhibitor aliskiren or a pharmaceutically acceptable salt thereof and at least one therapeutic agent selected from the group consisting of (vi) an aldosterone antagonist or a pharmaceutically acceptable salt thereof, (vii) an d…
USPTO Abstract
A pharmaceutical composition comprising the renin inhibitor aliskiren or a pharmaceutically acceptable salt thereof and at least one therapeutic agent selected from the group consisting of (vi) an aldosterone antagonist or a pharmaceutically acceptable salt thereof, (vii) an dual angiotensin converting enzyme/neutral endopetidase (ACE/NEP) inhibitor or a pharmaceutically acceptable salt thereof, and (viii) an endothelin antagonist or a pharmaceutically acceptable salt thereof; and a carrier.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.